Samik Pharmaceutical Company LTD. (KOSDAQ:014950)
South Korea flag South Korea · Delayed Price · Currency is KRW
16,350
-1,530 (-8.56%)
At close: Dec 5, 2025

KOSDAQ:014950 Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023
Period Ending
Dec '24 Dec '23
Net Income
3,5222,969
Depreciation & Amortization
1,3511,278
Loss (Gain) From Sale of Assets
-9.5-0.07
Asset Writedown & Restructuring Costs
23.8-
Loss (Gain) From Sale of Investments
-300.14-298.32
Stock-Based Compensation
263.5872.69
Provision & Write-off of Bad Debts
-2.68-65.12
Other Operating Activities
1,391696.68
Change in Accounts Receivable
558.63-1,117
Change in Inventory
-2,105-55.64
Change in Accounts Payable
251.69-827.43
Change in Income Taxes
--3.98
Change in Other Net Operating Assets
-559.9-400.44
Operating Cash Flow
4,3852,248
Operating Cash Flow Growth
95.04%-
Capital Expenditures
-842.32-1,374
Sale (Purchase) of Intangibles
-5.83-3.14
Investment in Securities
-1,613-120.5
Other Investing Activities
--70
Investing Cash Flow
-2,161-1,868
Long-Term Debt Repaid
-137.56-109.02
Net Debt Issued (Repaid)
-137.56-109.02
Issuance of Common Stock
672.3-
Dividends Paid
-281-140.5
Other Financing Activities
-1.02-
Financing Cash Flow
252.72-249.52
Miscellaneous Cash Flow Adjustments
--0
Net Cash Flow
2,477130.88
Free Cash Flow
3,543874.05
Free Cash Flow Growth
305.32%-
Free Cash Flow Margin
6.34%1.71%
Free Cash Flow Per Share
503.91124.52
Cash Interest Paid
12.0418.36
Cash Income Tax Paid
205.693.03
Levered Free Cash Flow
3,382-
Unlevered Free Cash Flow
3,389-
Change in Working Capital
-1,854-2,405
Source: S&P Global Market Intelligence. Standard template. Financial Sources.